Nathaniel Braman

Nathaniel Braman

Auto-generated profile, based on publicly available information

Nathaniel Braman

Case Western Reserve University, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
NBNathaniel M. Braman
Nathaniel M. Braman
MEMaryam Etesami
Maryam Etesami
PPPrateek Prasanna
Prateek Prasanna
CDChristina Dubchuk
Christina Dubchuk
HGHannah Gilmore
Hannah Gilmore
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases. Feature selection was used to identify a set of top pCR-associated features from within a training set (n = 78), which were then used to train multiple machine learning classifiers to predict the likelihood of pCR for a given patient. Classifiers were then independently tested on 39 patients. Experiments were repeated separately among hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+, HER2−) and triple-negative or HER2+ (TN/HER2+) tumors via threefold cross-validation to determine whether receptor status-specific analysis could improve classification performance. Among all patients, a combined intratumoral and peritumoral radiomic feature set yielded a maximum AUC of 0.78 ± 0.030 within the training set and 0.74 within the independent testing set using a diagonal linear discriminant analysis (DLDA) classifier. Receptor status-specific feature discovery and classification enabled improved prediction of pCR, yielding maximum AUCs of 0.83 ± 0.025 within the HR+, HER2− group using DLDA and 0.93 ± 0.018 within the TN/HER2+ group using a naive Bayes classifier. In HR+, HER2− breast cancers, non-pCR was characterized by elevated peritumoral heterogeneity during initial contrast enhancement. However, TN/HER2+ tumors were best characterized by a speckled enhancement pattern within the peritumoral region of nonresponders. Radiomic features were found to strongly predict pCR independent of choice of classifier, suggesting their robustness as response predictors. Through a combined intratumoral and peritumoral radiomics approach, we could successfully predict pCR to NAC from pretreatment breast DCE-MRI, both with and without a priori knowledge of receptor status. Further, our findings suggest that the radiomic features most predictive of response vary across different receptor subtypes.

5 April 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
NBNathaniel Braman
Nathaniel Braman
PPPrateek Prasanna
Prateek Prasanna
JWJon Whitney
Jon Whitney
Salendra SinghSalendra Singh
Salendra Singh
NBNiha Beig
Niha Beig
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
Human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study)–positive breast cancer is morphologically and genetically heterogeneous. Not all patients will fully benefit from HER2-targeted treatment, with less than 35% of patients initially responding to therapy with the monoclonal antibody trastuzumab.1,2 Molecular profiling via tests such as the PAM50 gene set can provide insight into treatment response by subcategorizing HER2-positive (HER2+) tumors into response-associated intrinsic molecular subtypes.3-8 The HER2-enriched (HER2-E) subtype, composing 40% to 50% of HER2+ breast cancers, is of particular therapeutic interest owing to its elevated rate of response to HER2-targeted therapy.3,9,10 Although molecular subtyping of HER2+ breast cancer is gradually gaining biological significance, no clinically accepted biomarkers are as yet available for prediction of response to anti-HER2 therapy.11 Therefore, there remains a need to develop novel approaches to estimate clinical outcomes of HER2-targeted therapy.

1 March 2019 in Radiology
Verified
Journal Article
Closed access
NBNiha Beig
Niha Beig
MKMohammadhadi Khorrami
Mohammadhadi Khorrami
MAMehdi Alilou
Mehdi Alilou
PPPrateek Prasanna
Prateek Prasanna
NBNathaniel Braman
Nathaniel Braman
AMAnant Madabhushi
Anant Madabhushi
Perinodular and intranodular radiomic features corresponding to texture and shape (radiomics) were evaluated to distinguish non-small cell lung cancer adenocarcinomas from benign granulomas at nonc... PurposeTo evaluate ability of radiomic (computer-extracted imaging) features to distinguish non-small cell lung cancer adenocarcinomas from granulomas at noncontrast CT.Materials and MethodsFor thi...

15 April 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NBNiha Beig
Niha Beig
KBKaustav Bera
Kaustav Bera
PPPrateek Prasanna
Prateek Prasanna
JAJacob Antunes
Jacob Antunes
RCRamon Correa
Ramon Correa
PTPallavi Tiwari
Pallavi Tiwari
Purpose: To (i) create a survival risk score using radiomic features from the tumor habitat on routine MRI to predict progression-free survival (PFS) in glioblastoma and (ii) obtain a biological basis for these prognostic radiomic features, by studying their radiogenomic associations with molecular signaling pathways.Experimental Design: Two hundred three patients with pretreatment Gd-T1w, T2w, T2w-FLAIR MRI were obtained from 3 cohorts: The Cancer Imaging Archive (TCIA; n = 130), Ivy GAP (n = 32), and Cleveland Clinic (n = 41). Gene-expression profiles of corresponding patients were obtained for TCIA cohort. For every study, following expert segmentation of tumor subcompartments (necrotic core, enhancing tumor, peritumoral edema), 936 3D radiomic features were extracted from each subcompartment across all MRI protocols. Using Cox regression model, radiomic risk score (RRS) was developed for every protocol to predict PFS on the training cohort (n = 130) and evaluated on the holdout cohort (n = 73). Further, Gene Ontology and single-sample gene set enrichment analysis were used to identify specific molecular signaling pathway networks associated with RRS features.Results: Twenty-five radiomic features from the tumor habitat yielded the RRS. A combination of RRS with clinical (age and gender) and molecular features (MGMT and IDH status) resulted in a concordance index of 0.81 (P < 0.0001) on training and 0.84 (P = 0.03) on the test set. Radiogenomic analysis revealed associations of RRS features with signaling pathways for cell differentiation, cell adhesion, and angiogenesis, which contribute to chemoresistance in GBM.Conclusions: Our findings suggest that prognostic radiomic features from routine Gd-T1w MRI may also be significantly associated with key biological processes that affect response to chemotherapy in GBM.

27 February 2018
Verified
Conference Paper
Closed access
PDF file
KRKavya Ravichandran
Kavya Ravichandran
NBNathaniel Braman
Nathaniel Braman
AJAndrew Janowczyk
Andrew Janowczyk
AMAnant Madabhushi
Anant Madabhushi
Neoadjuvant chemotherapy (NAC) is routinely used to treat breast tumors before surgery to reduce tumor size and improve outcome. However, no current clinical or imaging metrics can effectively predict before treatment which NAC recipients will achieve pathological complete response (pCR), the absence of residual invasive disease in the breast or lymph nodes following surgical resection. In this work, we developed and applied a convolu- tional neural network (CNN) to predict pCR from pre-treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) scans on a per-voxel basis. In this study, DCE-MRI data for a total of 166 breast cancer pa- tients from the ISPY1 Clinical Trial were split into a training set of 133 patients and a testing set of 33 patients. A CNN consisting of 6 convolutional blocks was trained over 30 epochs. The pre-contrast and post-contrast DCE-MRI phases were considered in isolation and conjunction. A CNN utilizing a combination of both pre- and post-contrast images best distinguished responders, with an AUC of 0.77; 82% of the patients in the testing set were correctly classified based on their treatment response. Within the testing set, the CNN was able to produce probability heatmaps that visualized tumor regions that most strongly predicted therapeutic response. Multi- variate analysis with prognostic clinical variables (age, largest diameter, hormone receptor and HER2 status), revealed that the network was an independent predictor of response (p=0.05), and that the inclusion of HER2 status could further improve capability to predict response (AUC = 0.85, accuracy = 85%).

9 February 2017 in Journal of Proteome Research
Verified
Journal Article
Closed access
JNJeremy L. Norris
Jeremy L. Norris
MFMelissa A. Farrow
Melissa A. Farrow
DGDanielle B. Gutierrez
Danielle B. Gutierrez
LPLauren D. Palmer
Lauren D. Palmer
NMNicole Muszynski
Nicole Muszynski
RCRichard M. Caprioli
Richard M. Caprioli